Analysts expect DENTSPLY SIRONA Inc (NASDAQ:XRAY) to report sales of $943.24 million for the current fiscal quarter, according to Zacks. Seven analysts have made estimates for DENTSPLY SIRONA’s earnings. The lowest sales estimate is $929.30 million and the highest is $972.60 million. DENTSPLY SIRONA reported sales of $928.40 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 1.6%. The company is scheduled to issue its next quarterly earnings results on Thursday, November 14th.
On average, analysts expect that DENTSPLY SIRONA will report full-year sales of $3.99 billion for the current year, with estimates ranging from $3.97 billion to $4.01 billion. For the next year, analysts forecast that the business will post sales of $4.12 billion, with estimates ranging from $4.10 billion to $4.15 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for DENTSPLY SIRONA.
DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings data on Friday, August 2nd. The medical instruments supplier reported $0.66 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.04. DENTSPLY SIRONA had a return on equity of 9.19% and a net margin of 2.67%. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1.04 billion. During the same quarter last year, the firm earned $0.60 EPS. DENTSPLY SIRONA’s revenue for the quarter was down 3.1% compared to the same quarter last year.
XRAY has been the topic of several recent research reports. Zacks Investment Research lowered DENTSPLY SIRONA from a “buy” rating to a “hold” rating and set a $62.00 price objective on the stock. in a report on Monday, May 27th. HC Wainwright reissued a “neutral” rating and set a $57.00 price objective (up previously from $55.00) on shares of DENTSPLY SIRONA in a report on Tuesday, July 9th. BidaskClub raised DENTSPLY SIRONA from a “sell” rating to a “hold” rating in a report on Friday. Evercore ISI initiated coverage on DENTSPLY SIRONA in a report on Friday, July 26th. They set an “in-line” rating on the stock. Finally, Wolfe Research initiated coverage on DENTSPLY SIRONA in a report on Thursday, May 30th. They set a “peer perform” rating on the stock. Nine analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $54.57.
Shares of NASDAQ:XRAY traded up $0.06 during trading on Tuesday, hitting $52.33. 1,300,600 shares of the stock were exchanged, compared to its average volume of 1,933,085. DENTSPLY SIRONA has a 1-year low of $33.93 and a 1-year high of $59.40. The company has a market capitalization of $11.72 billion, a price-to-earnings ratio of 26.03, a price-to-earnings-growth ratio of 1.91 and a beta of 0.97. The company’s fifty day simple moving average is $55.56 and its 200-day simple moving average is $51.79. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.39 and a current ratio of 2.08.
In other DENTSPLY SIRONA news, Director Gregory T. Lucier acquired 10,000 shares of DENTSPLY SIRONA stock in a transaction on Thursday, May 23rd. The shares were bought at an average price of $53.60 per share, with a total value of $536,000.00. Following the completion of the purchase, the director now owns 10,000 shares in the company, valued at $536,000. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Betsy D. Holden acquired 2,720 shares of DENTSPLY SIRONA stock in a transaction on Thursday, June 6th. The stock was acquired at an average cost of $55.31 per share, for a total transaction of $150,443.20. Following the purchase, the director now owns 9,224 shares of the company’s stock, valued at approximately $510,179.44. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 22,720 shares of company stock worth $1,223,243. 0.62% of the stock is owned by insiders.
Institutional investors have recently bought and sold shares of the business. Altshuler Shaham Ltd boosted its stake in DENTSPLY SIRONA by 209.8% in the second quarter. Altshuler Shaham Ltd now owns 505 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 342 shares in the last quarter. Hanseatic Management Services Inc. acquired a new position in DENTSPLY SIRONA in the first quarter worth $30,000. Cornerstone Advisors Inc. boosted its stake in DENTSPLY SIRONA by 62.0% in the second quarter. Cornerstone Advisors Inc. now owns 904 shares of the medical instruments supplier’s stock worth $53,000 after purchasing an additional 346 shares in the last quarter. Van ECK Associates Corp acquired a new position in DENTSPLY SIRONA in the second quarter worth $54,000. Finally, Arcadia Investment Management Corp MI acquired a new position in DENTSPLY SIRONA in the second quarter worth $58,000. 97.06% of the stock is currently owned by institutional investors.
DENTSPLY SIRONA Company Profile
DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.
See Also: What does a hold rating mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.